Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Academic Article uri icon

Overview

abstract

  • BACKGROUND: The results of pulmonary transplantation are compromised by acute and chronic rejection. We hypothesized that a liposomal form of aerosolized cyclosporine A (CsA) would be selectively deposited and concentrated in the lungs. The theoretical advantage of this therapy is selective pulmonary immunosuppression with prolonged utilization. METHODS: Eighteen dogs were endotracheally intubated; aerosolized liposomal CsA was administered for 15 min. CsA levels were measured in whole blood, lung, trachea, heart, kidney, liver, and spleen at various times after treatment. RESULTS: The lung rapidly absorbs aerosolized liposomal CsA; other organs have much lower concentrations. The retention of pulmonary CsA delivered by liposome aerosol is approximately 120 min in this model. CONCLUSIONS: Aerosolized liposomal CsA is selectively deposited and concentrated in the lungs; other organs absorb less CsA.

publication date

  • December 1, 1999

Research

keywords

  • Cyclosporine
  • Immunosuppressive Agents
  • Lung Transplantation

Identity

Scopus Document Identifier

  • 0033386038

Digital Object Identifier (DOI)

  • 10.1016/s0003-4975(99)01183-2

PubMed ID

  • 10616974

Additional Document Info

volume

  • 68

issue

  • 6